|
시장보고서
상품코드
1789384
세계의 알도스테론 합성효소 억제제 시장 : 약제 유형별, 약물별, 적응증별, 개발 단계별, 성별, 최종 사용자별, 지역별(2025-2032년)Aldosterone Synthase Inhibitors Market, By Drug Type, By Drug, By Indication, By Stage of Development, By Gender, By End User, By Geography |
||||||
세계의 알도스테론 합성효소 억제제 시장은 2025년 2억 2,590만 달러로 추정되고, 2032년까지 3억 6,960만 달러에 이를 것으로 예측되고, 예측 기간 중 연평균 성장률(CAGR) 7.3%를 보일 것으로 예측됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 시장 규모(2025년) | 2억 2,590만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측기간 CAGR(2025-2032년) | 7.30% | 예측 금액(2032년) | 3억 6,960만 달러 |
알도스테론 합성효소 억제제 세계 시장은 알도스테론의 과잉 생산과 관련된 심혈관 질환과 신장 질환의 치료 솔루션 개발에 중점을 둔 전문 의약품 부문입니다. 알도스테론 합성효소는 CYP11B2로도 알려져 있으며 부신 피질 내에서 알도스테론 생합성의 최종 단계를 담당하는 중요한 효소입니다. 이 효소를 표적으로 하는 억제제는 원발성 알도스테론증, 저항성 고혈압, 심부전, 만성 신장병 등의 치료제로서 유망합니다. 이러한 억제제는 코르티솔의 합성을 유지하면서 알도스테론의 생산을 선택적으로 억제함으로써 작용하며, 기존 미네랄 코르티코이드 수용체 길항제와 비교하여 보다 적은 접근법을 제공합니다.
시장은 전임상 연구부터 임상시험까지 다양한 개발 단계에 있으며, 여러 제약 회사가 이 치료 영역에 많은 투자를 하고 있습니다. 심혈관계의 병태생리에서 알도스테론의 역할에 대한 이해의 심화와 현재의 치료 선택의 한계로부터 이 분야에서의 연구 노력이 활발해지고 있습니다. 시장 성장의 주요 요인은 심혈관 질환의 유병률 증가, 원발성 알도스테론증에 대한 의식 증가, 보다 효과적인 치료 옵션의 필요성입니다. 선택적 알도스테론 합성효소 억제제의 개발은 알도스테론 관련 질환을 관리하기 위한 정밀의료 접근법에서 중요한 진보입니다.
시장 역학
세계의 알도스테론 합성효소 억제제 시장은 여러 요인에 의해 큰 성장을 이루고 있지만, 그 주요 요인은 세계의 심혈관 질환, 특히 내성 고혈압과 심부전의 유병률 증가입니다. 1차성 알도스테론증이 2차성 고혈압의 원인으로서 종래 생각되고 있던 것보다 일반적이며, 고혈압 환자의 약 10-15%가 이환되고 있다고 하는 인식이 퍼지고 있기 때문에 표적 치료적 개입제로서의 알도스테론 합성효소 억제제에 대한 연구의 주목이 높아지고 있습니다.
게다가 고칼륨혈증이나 호르몬 분비장해 등 미네랄 코르티코이드 수용체 길항제에 따른 부작용 등 기존 치료법에는 한계가 있기 때문에 보다 선택적인 치료 접근법을 요구하는 기회가 탄생하고 있습니다. 그러나 신규 효소 억제제의 복잡한 규제경로, 많은 연구개발비, 승인까지 몇 년이 걸리는 임상시험 프로세스 등 시장은 큰 억제요인에 직면하고 있습니다. 다른 스테로이드 생성 효소에 대한 간섭을 피하면서 알도스테론 합성효소를 효과적으로 표적으로 하는 선택적 억제제의 개발에 수반되는 기술적 과제는 제약기업에 있어서 더욱 장애물이 되고 있습니다. 게다가 이 치료 영역은 특별하기 때문에 광범위한 임상 전문 지식과 인프라가 필요하며, 이러한 개발을 추구할 수 있는 기업의 수는 한정되어 있습니다.
이러한 과제에도 불구하고 심혈관 연구에 대한 투자 증가, 제약 기업과 학술 기관의 파트너십 확대, 고혈압 이외의 다양한 질병 상태에서 알도스테론의 역할 이해 확대, 치료 효과와 환자의 결과를 개선할 수 있는 병용 요법의 가능성 등의 형태로 기회는 풍부합니다.
이 보고서의 주요 특징
- 본 보고서는 세계의 알도스테론 합성효소 억제제 시장을 상세하게 분석하여 2024년을 기준 연도로 한 예측기간(2025-2032년) 시장 규모 및 CAGR을 제공합니다.
- 또한 각 부문의 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 행렬을 설명합니다.
- 또한 시장 성장 촉진요인 및 억제요인과 기회, 신제품의 출시와 승인, 시장 동향, 지역별 전망, 주요기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 세계의 알도스테론 합성효소 억제제 시장의 주요 기업 프로파일은 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등 다음 매개변수를 기반으로 게재됩니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 제휴, 시장 확대, 마케팅 전술에 대한 충분한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- '세계의 알도스테론 합성효소 억제제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
- 이해관계자들은 세계의 알도스테론 합성효소 억제제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
- 분석 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 성장 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 출시/승인
- PEST 분석
- Porter's Five Forces 분석
- 기업 인수합병(M&A) 시나리오
- 업계 동향
- 파이프라인 분석
- 봉쇄 매핑
- 체스보드 매핑
- 기업 포지셔닝 분석
- 비교 매트릭스
제4장 세계의 알도스테론 합성효소 억제제 시장 : 약제 유형별(금액 기준, 2020-2032년)
- 선택적 알도스테론 합성효소 억제제
- 비선택적 CYP11B 억제제
제5장 세계의 알도스테론 합성효소 억제제 시장 : 약물별(금액 기준, 2020-2032년)
- Osilodrostat
- Lorundrostat
- Baxdrostat
- Vicadrostat
- Dexfadrostat
제6장 세계의 알도스테론 합성효소 억제제 시장 : 적응증별(금액 기준, 2020-2032년)
- 쿠싱 증후군
- 고혈압
- 원발성 알도스테론증(콘 증후군)
- 심부전
- 전이성 호르몬 감수성 전립선암(mHSPC)
제7장 세계의 알도스테론 합성효소 억제제 시장 : 개발 단계별(금액 기준, 2020-2032년)
- 전임상
- 제I상 임상시험
- 제II상 임상시험
- 제III상 임상시험
- 승인 및 출시완료
제8장 세계의 알도스테론 합성효소 억제제 시장 : 성별(금액 기준, 2020-2032년)
- 남성
- 여성
제9장 세계의 알도스테론 합성효소 억제제 시장 : 최종 사용자별(금액 기준, 2020-2032년)
- 병원
- 심장병 클리닉
- 신장 내과 클리닉
- 연구 및 학술기관
- CRO(의약품 개발 업무 수탁 기관)
제10장 세계의 알도스테론 합성효소 억제제 시장 : 지역별(금액 기준, 2020-2032년)
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙 아프리카
제11장 경쟁 구도
- Mineralys Therapeutics, Inc.
- AstraZeneca
- Boehringer Ingelheim International GmbH
- DAMIAN PHARMA AG
- CORXEL
- JX09
- Recordati Rare Diseases Inc.
- Other Prominent Players
제12장 애널리스트의 제안
- 「운명의 고리」
- 애널리스트의 견해
- Coherent Opportunity Map(COM)
제13장 참고문헌과 조사방법
- 참고문헌
- 분석 방법
- Coherent Market Insights에 대해
Aldosterone Synthase Inhibitors Market is estimated to be valued at USD 225.9 Mn in 2025 and is expected to reach USD 369.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 225.9 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.30% | 2032 Value Projection: | USD 369.6 Mn |
The global aldosterone synthase inhibitors market represents a specialized pharmaceutical segment focused on developing therapeutic solutions for cardiovascular and renal diseases associated with aldosterone overproduction. Aldosterone synthase, also known as CYP11B2, is a crucial enzyme responsible for the final step in aldosterone biosynthesis within the adrenal cortex. Inhibitors targeting this enzyme offer promising therapeutic potential for treating conditions such as primary aldosteronism, resistant hypertension, heart failure, and chronic kidney disease. These inhibitors work by selectively blocking aldosterone production while preserving cortisol synthesis, providing a more targeted approach compared to traditional mineralocorticoid receptor antagonists.
The market encompasses various developmental stages, from preclinical research to clinical trials, with several pharmaceutical companies investing significantly in this therapeutic area. The growing understanding of aldosterone's role in cardiovascular pathophysiology and the limitations of current treatment options have intensified research efforts in this field. Market growth is primarily driven by increasing prevalence of cardiovascular diseases, rising awareness about primary aldosteronism, and the need for more effective therapeutic alternatives. The development of selective aldosterone synthase inhibitors represents a significant advancement in precision medicine approaches for managing aldosterone-related disorders.
Market Dynamics
The global aldosterone synthase inhibitors market is experiencing significant growth driven by multiple factors, with the primary driver being the increasing prevalence of cardiovascular diseases worldwide, particularly resistant hypertension and heart failure, which affects millions of patients globally and creates substantial demand for innovative therapeutic solutions. The growing recognition of primary aldosteronism as a more common cause of secondary hypertension than previously thought, affecting approximately 10-15% of hypertensive patients, has intensified research focus on aldosterone synthase inhibitors as targeted therapeutic interventions.
Additionally, the limitations of existing treatments, including side effects associated with mineralocorticoid receptor antagonists such as hyperkalemia and hormonal disturbances, create opportunities for more selective therapeutic approaches. However, the market faces significant restraints including complex regulatory pathways for novel enzyme inhibitors, substantial research and development costs, and lengthy clinical trial processes that can extend over several years before market approval. The technical challenges associated with developing selective inhibitors that effectively target aldosterone synthase while avoiding interference with other steroidogenic enzymes present additional hurdles for pharmaceutical companies. Furthermore, the specialized nature of this therapeutic area requires extensive clinical expertise and infrastructure, limiting the number of companies capable of pursuing these developments.
Despite these challenges, opportunities abound in the form of increasing investment in cardiovascular research, growing partnerships between pharmaceutical companies and academic institutions, expanding understanding of aldosterone's role in various disease states beyond hypertension, and the potential for combination therapies that could enhance treatment efficacy and patient outcomes.
Key Features of the Study
- This report provides in-depth analysis of the global aldosterone synthase inhibitors market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global aldosterone synthase inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include major pharmaceutical companies, biotechnology firms, and research institutions actively involved in aldosterone synthase inhibitor development.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global aldosterone synthase inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global aldosterone synthase inhibitors market.
Market Segmentation
- Drug Type Insights (Revenue, USD Mn, 2020 - 2032)
- Selective Aldosterone Synthase Inhibitors
- Non-Selective CYP11B Inhibitors
- Drug Insights (Revenue, USD Mn, 2020 - 2032)
- Osilodrostat
- Lorundrostat
- Baxdrostat
- Vicadrostat
- Dexfadrostat
- Indication Insights (Revenue, USD Mn, 2020 - 2032)
- Cushing's Syndrome
- Hypertension
- Primary aldosteronism (Conn's syndrome)
- Heart Failure
- Heart Failure with Reduced Ejection Fraction (HFrEF)
- Heart Failure with Preserved Ejection Fraction (HFpEF)
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Stage of Development Insights (Revenue, USD Mn, 2020 - 2032)
- Preclinical
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Approved or Marketed
- Gender Insights (Revenue, USD Mn, 2020 - 2032)
- Male
- Female
- End User Insights (Revenue, USD Mn, 2020 - 2032)
- Hospitals
- Cardiology Clinics
- Nephrology Clinics
- Research and Academic Institutes
- Contract Research Organizations (CROs)
- Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Mineralys Therapeutics, Inc.
- AstraZeneca
- Boehringer Ingelheim International GmbH
- DAMIAN PHARMA AG
- CORXEL
- JX09
- Recordati Rare Diseases Inc.
- Other Prominent Players
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Aldosterone Synthase Inhibitors Market, By Drug Type
- Global Aldosterone Synthase Inhibitors Market, By Drug
- Global Aldosterone Synthase Inhibitors Market, By Indication
- Global Aldosterone Synthase Inhibitors Market, By Stage of Development
- Global Aldosterone Synthase Inhibitors Market, By Gender
- Global Aldosterone Synthase Inhibitors Market, By End User
- Global Aldosterone Synthase Inhibitors Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
- Pipeline Analysis
- Blockade Mapping
- Chessboard Mapping
- Company Positioning Analysis
- Comparative Matrix
4. Global Aldosterone Synthase Inhibitors Market, By Drug Type, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Selective Aldosterone Synthase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Non-Selective CYP11B Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
5. Global Aldosterone Synthase Inhibitors Market, By Drug, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Osilodrostat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Lorundrostat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Baxdrostat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Vicadrostat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Dexfadrostat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
6. Global Aldosterone Synthase Inhibitors Market, By Indication, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Cushing's Syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Primary aldosteronism (Conn's syndrome)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Heart Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Heart Failure with Reduced Ejection Fraction (HFrEF)
- Heart Failure with Preserved Ejection Fraction (HFpEF)
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
7. Global Aldosterone Synthase Inhibitors Market, By Stage of Development, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Preclinical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Phase I Clinical Trials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Phase II Clinical Trials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Phase III Clinical Trials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Approved or Marketed
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
8. Global Aldosterone Synthase Inhibitors Market, By Gender, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
9. Global Aldosterone Synthase Inhibitors Market, By End User, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Cardiology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Nephrology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Research and Academic Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
10. Global Aldosterone Synthase Inhibitors Market, By Region, 2020 - 2032, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2032, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Mineralys Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- DAMIAN PHARMA AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CORXEL
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- JX09
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Recordati Rare Diseases Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Other Prominent Players
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
(주말 및 공휴일 제외)
